HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Ultratard Insulin

Long acting human insulin zinc supension

Also Known As:

Insulin, Ultratard; Depinsulin; Superdepinsulin

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Peptide Hormones: 1347
    - Pancreatic Hormones: 113
      - Insulins: 644
        Proinsulin: 1195
        Insulin: 113363
        Ultratard Insulin: 4
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Peptide Hormones: 1347
    - Pancreatic Hormones: 113
      - Insulins: 644
        Proinsulin: 1195
        Insulin: 113363
        Ultratard Insulin: 4

Related Diseases

1.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/20/1987 - "A trial was undertaken to ascertain the effect and acceptability of a multiple insulin injection regimen (MII) in patients with insulin-dependent diabetes mellitus using short-acting monocomponent human soluble insulin (Actrapid HM; Novo) for pre-meal bolus injections with the NovoPen injection device (Novo) and long-acting human insulin (Ultratard HM; Novo) at bedtime. " 02/01/1992 - "To evaluate whether an insulin regimen with a long-acting zinc insulin (Ultratard HM) could help control fasting hyperglycemia in insulin-dependent diabetes mellitus (IDDM) patients. " 01/01/1987 - "To investigate whether morning or evening injection of a long-acting insulin preparation (Ultratard HM, Novo) affects the glycaemic control in insulin-dependent diabetic (IDDM) patients, 24-hour blood glucose and plasma free insulin profiles were obtained in nine C-peptide negative IDDMs after one daily injection of insulin Ultratard HM either before breakfast (0800 h) or at 2200 h during the preceding 14 days. "
2.	Hyperglycemia 02/01/1992 - "To evaluate whether an insulin regimen with a long-acting zinc insulin (Ultratard HM) could help control fasting hyperglycemia in insulin-dependent diabetes mellitus (IDDM) patients. "
3.	Body Weight (Weight, Body) 11/01/1990 - "Metabolic control, insulin secretion and insulin action were evaluated in seven Type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral antidiabetic agents before and after two months of combined therapy with supper-time insulin (Ultratard: 0.4 U/kg body weight/day) plus premeal glibenclamide (15 mg/day). "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Long-Acting Insulin (Insulin, Long Acting)
3.	Zinc
4.	Hypoglycemic Agents (Hypoglycemics)
5.	Glyburide (Glibenclamide)
6.	C-Peptide
7.	Blood Glucose (Blood Sugar)

Related Therapies and Procedures

1.	Injections
2.	Therapeutics